Axio BioPharma and Likarda Join Forces for Innovative Biologic Drug Development

Axio BioPharma and Likarda Announce Strategic Partnership

In a groundbreaking announcement on June 9, 2025, Axio BioPharma Inc., a pioneering company in AI-powered biomanufacturing, and Likarda Inc., a prominent name in advanced drug delivery systems, have declared a strategic partnership aimed at revolutionizing the development and delivery of biologic drugs. This collaboration is poised to blend cutting-edge technologies from both companies, setting a new standard in the biopharmaceutical sector.

Strengthening Biologic Drug Development
The partnership will merge Axio BioPharma’s advanced protein manufacturing processes with Likarda’s innovative drug delivery solutions. This integration is intended to streamline the clinical manufacturing process, enhancing efficacy and scalability for clients in the biopharmaceutical industry. By leveraging Likarda’s proprietary technologies, particularly the Core-Shell Spherification® (CSS®) hydrogel technology, the partnership aims to bring significant improvements in encapsulation, stability, and controlled release of therapeutics.

Justin Byers, the CEO of Axio BioPharma, expressed his enthusiasm about the partnership, stating, "This collaboration infuses delivery innovation into the drug development workflow. It will enable our clients to make more informed decisions efficiently and expediently. We are working to reduce delays, shorten timelines, and deliver integrated solutions that align closely with our clients' objectives."

Innovative Solutions from Day One
Dr. Stella Vnook, CEO of Likarda, echoed Byers’ sentiment, emphasizing the significance of incorporating delivery strategies early in the drug development lifecycle. She stated, "At Likarda, we understand that delivery is an integral part of the development process. This alignment with Axio equips us to integrate our encapsulation technologies sooner, enhancing stability and efficacy, leading to improved patient experiences. Together, we’re crafting a connected pathway from research discovery to clinical application."

This synergy not only bolsters Axio's commitment to remapping biologic drug manufacturing through predictive analytics and digital-first processes but also allows Likarda to employ its delivery innovations at earlier stages, resulting in heightened efficiencies and a broader scope of therapeutic applications.

Advantages Highlighted by the Partnership

1. Enhanced Collaboration: This joint effort symbolizes a commitment to redefining how biologics are developed and delivered.
2. Integrated Solutions: By combining manufacturing and delivery technologies, both companies offer clients a streamlined development process.
3. Speed and Efficiency: The partnership aims to significantly cut development timelines, facilitating faster market access for novel therapies.
4. Customizable Technologies: Likarda’s CSS® platform allows for tailored solutions that address specific therapeutic needs, reinforcing drug stability, and optimizing release profiles.

In adapting to the ever-evolving biopharmaceutical landscape, the Axio-Likarda alliance symbolizes a forward-thinking approach to drug development that prioritizes efficiency and patient outcomes. By merging their respective strengths, the two companies are poised to open new avenues for the creation and application of biologics, promoting improved health solutions for patients facing chronic and life-threatening conditions.

Conclusion

In conclusion, this strategic partnership between Axio BioPharma and Likarda represents a promising leap forward in the realms of biologic drug development and delivery. As the collaboration unfolds, stakeholders across the biopharmaceutical sector are keenly watching how this alliance will pave the way for innovative therapies, potentially transforming the treatment landscape for numerous diseases. Through their joint expertise, Axio and Likarda are committed to pushing the frontiers of biologic therapies, ensuring that advanced treatments become more accessible and effective for patients in need.